A new 4-nitrobenzyl carbonate prodrug of methyl 5-benzyl-2-hydroxy-11-methylene-6-oxo-5H-benzo[b]carbazole-1-carboxylate for potential use with nitroreductase-based gene-directed enzyme prodrug therapy (GDEPT).
A tumour-selective 4-nitrobenzyloxycarbonyl prodrug methyl 5-benzyl-2-hydroxy-11-methylene-6-oxo-5H-benzo[b]carbazole-1-carboxylate was synthezised for gene-directed enzyme prodrug therapy (GDEPT). The compound is a substrate for E. coli nitroreductase.
Asche
C
C
LEDSS, UMR CNRS 5616, Université Joseph Fourier, Grenoble, France. Christian.asche@gmx.net
Kucklaender
U
U
D002227:Carbazoles / Q000737:chemistry* / Q000378:metabolism; D002264:Carboxylic Acids / Q000737:chemistry* / Q000378:metabolism; D057487:Enzyme Therapy; D004798:Enzymes / Q000008:administration & dosage; D004926:Escherichia coli / Q000201:enzymology; D015316:Genetic Therapy; D009601:Nitroreductases / Q000378:metabolism*; D011355:Prodrugs
D002227:Carbazoles; D002264:Carboxylic Acids; D004798:Enzymes; D011355:Prodrugs; C510051:methyl 5-benzyl-2-hydroxy-11-methylene-6-oxo-5H-benzo(b)carbazole-1-carboxylate; D009601:Nitroreductases